课题基金 / 基金详情

Development and preclinical validation of first-in-class dual inhibitors of the atypical MAP kinases ERK3 and ERK4

Development and preclinical validation of first-in-class dual inhibitors of the atypical MAP kinases ERK3 and ERK4
非典型 MAP 激酶 ERK3 和 ERK4 的一流双抑制剂的开发和临床前验证
批准号：
461610
负责人：
Meloche Sylvain
金额：
$69.66万
依托单位：
Institute for Research in Immunology and Cancer (Montreal, QC)
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2022
资助国家：
加拿大
项目状态：
未结题
起止时间：
2022-03-01 至 2027-03-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=461610&lang=en
关键词：
Cadd Chemical Biology Chemical Screens Drug Development Erk3/Erk4 Hit-To-Lead Chemistry Map Kinases Pharmacology Preclinical Evaluation Signal Transduction

项目摘要

项目成果

Meloche Sylvain的其他基金

相似基金

相关文献

中文摘要
翻译
蛋白激酶选择性化学抑制剂的开发对于了解蛋白激酶的作用机制和探索其在生理和疾病中的作用具有重要意义。这些化学工具对于验证潜在的药物靶点和
英文摘要
The development of selective chemical inhibitors of protein kinases is of key importance for understanding kinase mechanisms and exploring their roles in physiology and disease. These chemical tools are also essential to validate potential drug targets an
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role and therapeutic potential of the atypical MAP kinase ERK3 in basal-like breast cancer progression
Role and therapeutic potential of ERK3/ERK4 MAP kinases in acute kidney injury
Regulation, downstream targets and functional specificity of the MAP kinases ERK1 and ERK2
Targeting the degradation of the cyclin-dependent kinase inhibitor p21 as a novel approach to cancer therapy
海外基金